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Key points 63 
• Primary achalasia is a disorder due to neuronal defects supplying the 64 
esophagus leading to altered peristalsis and lack of sphincter relaxation. 65 
Nonetheless, the molecular mechanisms involved in this condition are poorly 66 
understood. 67 
 68 
• Transcriptomic analysis of achalasic tissues identified a dysregulated 69 
expression of different genes, in particular c-KIT (downregulated) and 70 
INPP4B (upregulated), the latter being linked to Akt pathway regulation. 71 
 72 
• Our results unravel novel signaling pathways involved in the neuronal and 73 
interstitial cells of Cajal abnormalities in primary achalasia. 74 





































































Background & Aims: Achalasia is a rare motility disorder characterized by myenteric 81 
neuron and interstitial cells of Cajal (ICC) abnormalities leading to deranged/absent 82 
peristalsis and lack of relaxation of the lower esophageal sphincter. The mechanisms 83 
contributing to neuronal and ICC changes in achalasia are only partially understood. 84 
Our goal was to identify novel molecular features occurring in patients with primary 85 
achalasia. 86 
Methods: Esophageal full-thickness biopsies from 42 (22 females; age range: 16-82 87 
yrs) clinically, radiologically and manometrically characterized patients with primary 88 
achalasia were examined and compared to those obtained from ten subjects (controls) 89 
undergoing surgery for uncomplicated esophageal cancer (or upper stomach 90 
disorders). Tissue RNA extracted from biopsies of cases and controls was used for 91 
library preparation and sequencing. Data analysis was performed with the 'edgeR' 92 
option of R-Bioconductor. Data were validated by real-time RT-PCR, western 93 
blotting and immunohistochemistry. 94 
Key Results: Quantitative transcriptome evaluation and cluster analysis revealed 111 95 
differentially expressed genes, with a P≤10
-3
. Nine genes with a P≤10
-4
 were further 96 
validated. CYR61, CTGF, c-KIT, DUSP5, EGR1 were downregulated, whereas 97 
AKAP6 and INPP4B were upregulated in patients vs controls. Compared to controls, 98 
immunohistochemical analysis revealed a clear increase in INPP4B, whereas c-KIT 99 
immunolabeling resulted downregulated. Since INPP4B regulates Akt pathway, we 100 
used western blot to show that phospho-Akt was significantly reduced in achalasia 101 
patients vs controls. 102 































































Conclusions & Inferences: The identification of altered gene expression, including 103 
INPP4B, a regulator of the Akt pathway, highlights novel signaling pathways 104 
involved in the neuronal and ICC changes underlying primary achalasia. 105 
 106 
Key words: Achalasia, cell signaling, c-KIT, INPP4B, transcriptome. 107 
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Introduction  109 
Achalasia is a primary motility disorder of the esophagus occurring at any age, with 110 
an estimated annual incidence of approximately 0.03-1 per 100 people and affecting 111 
both sexes equally.
1,2
 Achalasia can be classified into primary forms (mostly 112 
idiopathic), and cases associated with systemic disorders.
3,4
 From a pathogenetic 113 
stand-point, achalasia is characterized by a predominant loss of inhibitory myenteric 114 
neurons with a relative increase of cholinergic motorneurons
5
. Progressively 115 
degenerative processes may involve virtually all neurons over time. These neuronal 116 
changes result in an increase of the lower esophageal sphincter (LES) tone, which, in 117 
conjunction with an altered peristalsis of the esophageal body, represent the 118 
manometric correlate of any form of achalasia.
6
 Because of these functional 119 
abnormalities patients with achalasia complain of dysphagia, regurgitation and chest 120 
pain, often severe enough to require either surgery or pneumatic dilatation
7
. 121 
Mechanisms leading to esophageal myenteric neurodegeneration and loss include 122 
autoimmune responses likely triggered by environmental factors (e.g., neurotropic 123 
viruses) in genetically predisposed individuals.
2,3,8
 In addition to neurons, 124 
abnormalities of interstitial cells of Cajal (ICC), the pace-maker cells of the 125 




The current standard for diagnosing achalasia is high-resolution manometry, although 128 
molecular biomarkers would be useful not only for diagnostic purposes, but also to 129 
address targeted therapeutic options so far not yet available. Proteomic analysis of 130 
sera from patients with achalasia and healthy individuals showed disease-related 131 
upregulation of transthyretin (TTR), a carrier of thyroid hormone thyroxine and a 132 
retinol-binding protein, associated with familial amyloid polyneuropathy.
10
 The 133 































































observed upregulation may correlate with the consequent neural degeneration 134 
observed in achalasic patients.
11
 Other studies demonstrated increased deposits of the 135 




Achalasia due to rare genetic abnormalities includes recessive forms with mutations 138 
in the neuronal nitric oxide synthase gene, NOS1
13
, or in ALADIN gene
14
 (Allgrove 139 
syndrome or triple A syndrome, characterized by alacrima, achalasia and adrenal 140 
cortex failure; OMIM #231550). Genome-wide and candidate gene association 141 
studies have implicated the human leukocyte antigen (HLA) class II system as the 142 
underlying genetic predisposing factor in achalasia. In particular, an 8-residues 143 
insertion in the cytoplasmic tail of HLA-DQβ1 has been identified as a strong risk 144 
factor for achalasia, with a specific geospatial north-south gradient among 145 
Europeans.
15
 Two amino acid substitutions in the extracellular domain of HLA-146 
DQα1, (lysine 41 encoded by HLA-DQA1*01:03) and of HLA-DQβ1, (glutamic acid 147 
45, encoded by HLA-DQB1*03:01 and HLA-DQB1*03:04) were characterized as 148 
independent risk factors for achalasia and patients with the DQA1*0103 and 149 




Nevertheless, the mechanisms contributing to the observed neuronal and ICC changes 152 
in achalasia are still partially understood. The aim of this study was to identify the 153 
dysregulated molecular pathways / events occurring in primary (idiopathic) achalasia 154 
to provide a molecular signature of primary achalasia. 155 
 156 
Materials and Methods 157 
Patients and tissue biopsies 158 































































A number of 42 (n= 20 from Italy; n= 22 from Belgium; 22 females; age range: 16-82 159 
yrs) patients with a well-established clinical, radiological and manometric diagnosis 160 
of primary achalasia were recruited (Supplementary Table 1A). The included patients 161 
were all of Caucasian origin. Each patient underwent surgery and 1-2 tissue samples 162 
were obtained via a laparoscopic extramucosal Heller’s myotomy extended 4-5 cm 163 
along the distal esophagus (i.e., 1-2 cm full-thickness biopsy containing the circular 164 
and longitudinal muscle with the associated enteric nervous system). Comparable 165 
control tissues were obtained from the corresponding esophageal region of 10 (3 166 
females; age range: 45-87 yrs) controls, who were referred to surgery for 167 
uncomplicated esophageal cancer and upper stomach disorders, as reported in 168 
Supplementary Table 1B. Margins of all of sampled tissues were free of cancer. 169 
Signed informed consent was obtained for each subject enrolled in the study and data 170 
handling was performed according to the Helsinki declaration. The study was 171 
approved by the local Ethic Committee (study 42/2011/0/Oss protocol #877/211). 172 
RNA extraction 173 
Total RNA was extracted with the RiboPure kit from fresh frozen biopsies stored at -174 
80°C in RNAlater, according to the manufacturer’s instruction (Ambion, 175 
ThermoFisher Scientific, Waltham, MA, USA). RNA was resuspended in 40 µl of 176 
RNase-free water, and quality and quantity of RNA were evaluated on Agilent 177 
Bioanalyzer 2100 instrument (Agilent, Santa Clara, CA, USA). 150 ng of RNA was 178 
used for each library preparation, according to the TruSeq RNA Sample Prep v2 179 
protocol (Illumina, San Diego, CA, USA). Poly(A)-RNA molecules from 500 ng of 180 
total RNA were purified using oligo-dT magnetic beads. Following purification, the 181 
mRNA was fragmented and randomly primed for reverse transcription followed by 182 
second-strand synthesis to create double-stranded cDNA fragments, that were then 183 































































end-repaired and ligated using paired-end sequencing adapters. The products were 184 
then amplified to enrich for fragments carrying adapters ligated on both ends, thus 185 
creating the final cDNA library. RNAseq was performed on the HiScan SQ platform 186 
(Illumina) as 75 bp paired-end. 187 
RNAseq data analysis 188 
Raw paired-end reads obtained by the HiScan SQ were filtered and trimmed with the 189 
tool AdapterRemoval (http://code.google.com/p/adapterremoval/) to exclude low 190 
quality bases and sequence adapters. Short reads were mapped on human reference 191 
genome hg19 (https://genome.ucsc.edu/) with the pipeline Bowtie/Tophat 192 
(http://ccb.jhu.edu/software/tophat/index.shtml) and Samtools 193 
(http://samtools.sourceforge.net/) was adopted to remove optical/PCR duplicates. 194 
Gene expression quantification was performed with the Python package htseq-count 195 
(http://www-huber.embl.de/HTSeq/doc/overview.html) using the Ensembl release 72 196 
annotation features (http://www.ensembl.org). The raw counts were normalized with 197 
the R-Bioconductor package edger (function calcNormFactors) as “count per million” 198 
(cpm). A filter procedure was adopted to analyze only genes with cpm > 3 in at least 199 
2/4 samples. This process allowed to include 9616 genes, that were analyzed with the 200 
R-Bioconductor package limma to determine the differentially expressed genes. In 201 
particular, the function lmFit was used to fit the linear model, and the function eBayes 202 
was adopted to compute the moderate t-statistic. Genes were ranked in order of 203 
evidence for differential expression using log2 fold change (log2FC) and P value.
21
 204 
Multiple Experiment Viewer (MEV) (v4.8.1) was used to perform the analysis in two 205 
different ways: unsupervised hierarchical clustering (distance: Manhattan; clustering 206 
method: average) and principal component analysis. A total of 111 differentially 207 
expressed genes were selected (P≤ 10
-3
) for the evaluation of the functional 208 































































classification of biological processes and pathway over-representation, performed 209 
with the analytical tools PANTHER13.1 (Protein ANalysis THrough Evolutionary 210 
Relationships; http://pantherdb.org) and STRING. PANTHER is tightly integrated 211 
with a number of different genomic resources: the InterPro Consortium of protein 212 
classification resources, the Quest for Orthologs Consortium and the UniProt 213 
Reference Proteome data sets. PANTHER Over-representation tool includes 214 
functional annotations directly downloaded from the Gene Ontology (GO) 215 
Consortium, in addition to the phylogenetically inferred annotations.
22
 Analysis was 216 
performed using the option PANTHER Functional Classification and Over-217 
representation Tests, using the PANTHER GO-Slim Biological process and the 218 
Fisher's Exact with false discovery rate (FDR) multiple test correction for statistical 219 
analysis. Independent analysis to observe protein-protein interaction was performed 220 
with STRING, a database of known and predicted protein-protein interactions. The 221 
interactions include direct (physical) and indirect (functional) associations; stemming 222 
from computational prediction, from knowledge transfer between organisms, and 223 
from interactions aggregated from other (primary) databases.
23,24
 224 
Quantitative real-time RT-qPCR 225 
DNase I-treated RNA (200 ng) was used for reverse transcription (RT) with random 226 
hexamers using the Multiscribe RT system (ThermoFisher Scientific) at 48°C for 40 227 
min in a final volume of 50 µl. DNase I-treated total RNA was obtained from a pool 228 
of commercially available fresh frozen tissue biopsies of five controls subjects (single 229 
vial purchased from AMSBIO, Abingdon, Oxford, UK; reference code: R1234106-P, 230 
lot number B209050, human normal adult esophageal total RNA); the other RNAs 231 
were obtained from fresh frozen tissue biopsies as described above. 232 































































RT-qPCR was performed with SYBRGreen, 0.5 µM primers, in an ABI 7500 Real-233 
Time PCR System (ThermoFisher Scientific). All target genes were normalized with 234 
the endogenous control (beta-actin) using the ∆∆Ct comparative method. Primers are 235 
available from the Authors on request. 236 
Western blotting 237 
Proteins were extracted from fresh frozen tissue biopsies of esophagus of achalasia 238 
patients and controls by sonication using the Diagenode Bioruptor Pico sonicator 239 
System (V 1.1) (10 cycles of 30 on/30 off; 20-60 kHz), in a volume of 50 µl of Laemli 240 
buffer 1X. A pool of normal esophageal tissues was commercially available (Abcam, 241 
Cambridge, UK, reference code ab30243 - Human esophagus normal tissue lysate - 242 
total protein), the other tissues analyzed with western blotting were obtained from 243 
fresh frozen tissue biopsies of single cases and controls as reported in Supplementary 244 
Tables 1A and 1B. Proteins were visualized on Coomassie Blue gel for quality and 245 
quantity control. Western blot analysis was performed by SDS gel electrophoresis and 246 
transfer onto nitrocellulose membrane, using the TransBlot system (Bio-Rad 247 
Laboratories, Segrate, Italy). Primary antibodies used were the following: rabbit anti-248 
INPP4B diluted 1:200 (Abcam); rabbit anti-c-KIT (Abcam) diluted 1:200; mouse 249 
anti-vinculin (Sigma-Aldrich, St. Louis, MO, USA) diluted at 1:5000; mouse anti-250 
GAPDH 1:10000 (Abcam); anti p-Akt (Ser473), anti p-Akt (Thr308), anti Akt (Cell 251 
Signaling, Leiden, Netherlands), anti β-actin 1:10000 (Sigma-Aldrich). HRPO-252 
conjugated secondary antibodies (Sigma-Aldrich) were diluted 1:35000 in blocking 253 
solution. Bands were visualized by the ECL method Supernova (Cyanagen, Bologna, 254 
Italy) using the Chemidoc XRS+ Imager and densitometric analysis was performed 255 
with Image lab Software (Bio-Rad Laboratories). All western blot analyses were 256 































































performed at least in duplicate for each protein extract from each patient and control 257 
tissue biopsy.  258 
Immunohistochemistry 259 
Immunohistochemistry was performed on paraffin-embedded adult human esophagus 260 
tissues according to protocols validated in our laboratory.
25
 Immunohistochemistry 261 
analyses and image acquisitions were performed in our laboratory at the University of 262 
Bologna. Briefly, tissue sections were treated to remove paraffin embedding by 263 
sequential washes in xylene and graded ethanol. Antigen unmasking was performed 264 
by heating sections at 95°C in 10 mM Sodium citrate buffer, pH 6.0, for 10 min and 265 
subsequent cooling at room temperature for 30 min. To reduce endogenous 266 
peroxidases, tissue sections were treated with an ad hoc blocking kit (GeneTex Inc., 267 
Irvine, CA, USA) and incubated for 16 h at 4°C with the same primary antibodies 268 
used for western blotting, but diluted 1:50. 3,3'-diaminobenzidine staining was 269 
performed according to standard protocols (DAB500 IHC Select® kit, Merck 270 
Millipore, Darmstadt, Germany). Scores were assigned based on the intensity of DAB 271 
staining (0 = no staining; + = 10-50% staining; ++ = 50-90% staining; +++ = ≥90% 272 
staining of the areas; all images were acquired at 10x magnification) according to 273 
standard pathological assessment.
26
 Three expert observers independently evaluated 274 
the images (E.B., F.B. and R. De G.), and their analyses were blinded regarding 275 
control vs. achalasia state. Image capturing of achalasia and control tissues was 276 
performed on a Nikon microscope using DS-5M digital camera (Nikon Instruments, 277 
Düsseldorf, Germany).  278 
 279 
Statistical analysis 280 































































Quantitative difference in densitometry of western blots was performed with the 281 
Student’s t-test option of GraphPad Quickstat calculator; statistical differences for the 282 
scores assigned to IHC samples from tissue biopsies was performed with Fisher’s 283 
Test (4 x 2 contingency table) using the program Vassarstats. 284 
 285 
Results 286 
Whole transcriptome analysis via RNAseq 287 
Total RNA extracted from esophageal biopsies of four cases (2F; age range: 30-58 288 
yrs) and four controls (3F; age range: 27-50 yrs) was used for library preparation and 289 
sequencing on Illumina HiScan SQ platform. Raw data showing the total amount of 290 
reads/library and the mean coverage are reported in Supplementary Table 2, along 291 
with the mean coverage for each sample. Quantitative data analysis using 292 
Bioconductor from R package identified 111 genes with differential expression 293 
between cases and controls at a P≤ 10
-3
 (Table 1). Compared to controls, 77 genes 294 
were downregulated and 34 genes were upregulated in the achalasia group. 295 
Hierarchical clustering considering the 111 genes was performed using MEV v4.8.1. 296 
As shown in the heat map in Figure 1A, a concordant signature of up- and down-297 
regulation expression was evident between cases and controls. Analysis using 298 
PANTHER Functional classification test (PANTHER GO Slim Process) led us to 299 
functionally map a total of 109 out of the 111 differentially expressed genes to 300 
different biological processes, including, amongst others, cell adhesion, biogenesis, 301 
developmental, immune and metabolic processes and response to stimuli 302 
(http://www.pantherdb.org/chart/pantherChart.jsp?listType=1&filterLevel=1&type=2303 
&chartType=1&save=yes&basketItems=all&zoom=1.25&trackingId=4DCA8C9D00304 
F5C4649E3257CE82CFAC3E) (Figure 1B). PANTHER Over-representation Test 305 































































analysis was performed against the H. sapiens gene database, showing a set of over-306 
represented biological processes in achalasia, including, amongst others, 307 
phosphorylation, the MAPK cascade signaling (including intracellular signal 308 
transduction and cell communication), regulation of phosphate metabolism and 309 
developmental processes, e.g. cell differentiation and death (FDR< 0.05; Table 2).  310 
Network analysis was performed with STRING using the list of genes (the previously 311 
identified 111 genes) reported in Table 1, using the H. sapiens database as model 312 
organism, and the “whole genome” option as statistical background. A number of 104 313 
out of 111 genes matched the STRING protein database and were included in the 314 
analysis (https://string-db.org/cgi/network.pl?taskId=u9O5yLo4Lf2G). Several 315 
pathways were identified that showed a functional enrichment for biological 316 
processes, such as regulation of development, cell differentiation, angiogenesis and 317 
vascular architecture, with significant P values reported in Table 3. Many protein-318 
protein interactions converged on c-KIT (Figure 1C). 319 
Among the dysregulated genes in achalasia, those differentially expressed with a 320 
significant P≤ 10
-4
 were selected for further investigation, including CYR61, CTGF, 321 
c-KIT, EGR1, LIF and CD69 (downregulated); and AKAP6, and INPP4B 322 
(overexpressed) (Table 1). To validate the data from whole transcriptome analysis, we 323 
performed quantitative real-time RT-qPCR using the total RNA of already sequenced 324 
samples (including two patients and one control). For each real-time RT-qPCR, raw 325 
data were normalized on a commercial pool of human normal esophagus RNA from 326 
fresh frozen tissue biopsies of five individuals (AMSBIO), using the ∆∆Ct method. 327 
Data reported in Figure 1D show independent technical replicates (same case-control 328 
samples, independent retro-transcription and real-time processes). A significant 329 
dysregulation of expression was confirmed for c-KIT and INPP4B (Figure 1D). These 330 































































findings prompted us to focus on these two molecular targets, i.e. c-KIT and INPP4B, 331 
which were down- and up-regulated, respectively. 332 
 333 
Protein analysis of INPP4B and c-KIT confirmed the RNAseq data 334 
The protein expression of c-KIT and INPP4B was studied by western blotting. In 335 
these experiments, control samples included a pool of normal esophageal tissues 336 
(Abcam) from five subjects in addition to control tissues obtained from single 337 
individual control subjects. Western blotting analysis for each tissue lysate was 338 
performed at least in two independent experiments, i.e. technical replicates. Equal 339 
amount of proteins was loaded for each sample and intensities were normalized using 340 
reference proteins. Representative examples of the protein patterns observed for c-341 
KIT, INPP4B and reference proteins were reported in Figure 2A. Densitometric 342 
analysis of western blots was performed as indicated in Figure 2B. All cases and 343 
controls included in the western blotting analysis were reported in Supplementary 344 
Tables 1A and 1B. c-KIT downregulation was confirmed in tissue biopsies of 345 
achalasia patients compared to controls (P= 0.0003, Student’s t-test; Figure 2B), 346 
whereas INPP4B overexpression was significantly detectable in achalasia patients vs. 347 
controls (P=0.0381; Student’s t-test, Figure 2B). 348 
Immunohistochemistry analysis was performed in order to confirm the western blot 349 
data and to determine the cellular localization of the proteins herein identified by 350 
western blot. The density of c-KIT immunoreactive cells (mainly with the typical 351 
shape of ICC) was lower in achalasia than in controls (Fisher’s exact test, P= 0.0005, 352 
Figure 3A). Compared to controls, INPP4B immunoreactivity was more intense in 353 
achalasia patients. In INPP4B-positive cases, the immunoreactive signal was present 354 
in different cells including muscle cells and myenteric ganglia. INPP4B expression in 355 































































the normal tissues was very low or virtually absent (Fisher’s exact test, P= 0.0023; 356 
Figure 3B). 357 
 358 
Phospho-Akt is down regulated in achalasia 359 
As INPP4B is a negative regulator of Akt signaling, we investigated Akt 360 
phosphorylation status. Equal amount of proteins was loaded for each sample and 361 
intensities were normalized using reference proteins. Representative examples of the 362 
phosphorylation patterns observed for the two phosphorylation sites in Akt (Ser473, 363 
and Thr308) were reported in Figure 4A. Densitometric analysis, performed 364 
according to our previously published data,
27
 revealed that tissue samples from 365 
achalasia patients presented a reduced Akt phosphorylation, in particular the 366 
phosphorylation at Ser473 was significantly decreased compared to control tissues 367 
(P=0.0495, Student’s t-test; Figure 4B). 368 
 369 
Discussion 370 
Primary achalasia causes significant impairment of esophageal motility leading to 371 
symptom generation and overall reduced patients’ quality of life. This esophageal 372 
dysmotility of the esophagus has a complex etio-pathogenesis. Recent findings 373 
indicate that both an inflammatory / immune-mediated insult, as exhibited by 374 
myenteric ganglionitis (likely driven by neurotropic, e.g. herpes, virus infection)
28
 and 375 
circulating anti-neuronal antibodies, play a pathogenetic role. A genetic predisposition 376 
conferred by HLA genetic background
20
 can contribute to neural abnormalities 377 
underlying achalasia. A predominant genetic component has been identified in well-378 
defined conditions such as ‘triple A’ (also referred to Allgrove’s syndrome), where 379 
mutations in the ALADIN gene
14
 were found in familial clusters. Other data derive 380 































































from NOS1, which encodes for the neuronal nitric oxide synthase. A stop codon 381 
mutation of this gene has been reported in a family where two children manifested a 382 
very severe clinical phenotype dominated by achalasia.
13
 Nevertheless, in the majority 383 
of cases the factors causing achalasia remain to be elucidated. As a consequence, the 384 
available therapeutic approaches are far from targeting the actual mechanisms leading 385 
to the neural impairment recognized to be the primum movens of this severe 386 
esophageal disorder. New understanding of achalasia, involving a deeper knowledge 387 
of the attendant molecular mechanisms, should aim to a better patient management 388 
and stop the disease at early stages. Therefore, the present study attempted to decipher 389 
the altered molecular pathways in patients with achalasia. We strategically used 390 
esophageal tissues from achalasic patients and examined gene expression via whole 391 
transcriptome analysis in order to provide novel targets for a therapeutic approach. 392 
From the RNAseq data we detected 111 genes with an altered expression. Functional 393 
classification and over-representation analysis of the biological processes, where 394 
these genes mapped, was performed with two different bioinformatic tools, 395 
PANTHER and STRING. Results showed a significant over-representation of 396 
phosphorylation processes, intracellular signaling, cell communication and 397 
development /differentiation processes, including cell death. These data suggest that 398 
an imbalance of cell growth/survival vs. cell death may cause the defects observed in 399 
the achalasia tissues, not only in term of neuron loss, but also as an overall tissue 400 
degeneration. Notably, in a recent study, Palmieri et al. performed transcriptome 401 
analysis on tissues of primary achalasia patients and identified a significant 402 
enrichment of neuro-muscular and neuro-immune processes. These data support the 403 
concept that achalasia results from degenerative alterations / loss of myenteric 404 



































































Among the genes with significant dysregulation, we confirmed by real-time qPCR c-407 
KIT downregulation and INPP4B upregulation, respectively. c-KIT significant 408 
downregulation, validated both via western blot and immunohistochemistry, confirms 409 
and expands previously reported data showing a loss of ICC network in tissues of 410 
patients with primary achalasia.
9
 Our data highlighting a significant decrease of c-KIT 411 
expression in human achalasia support the concept that stem cell factor, the major 412 
ligand to c-KIT, cannot mediate ICC maintenance and survival. Although we did not 413 
look into specific apoptotic mechanisms, it is likely that a programmed cell death can 414 
involve ICC in achalasia.
30
 Since ICC play a role in esophageal motility, their 415 




The second gene for which we were able to confirm an altered expression at the 418 
protein level is INPP4B, encoding for inositol polyphosphate-4-phosphatase type II B, 419 
a negative regulator of Akt.
32,33
 The expression of this phosphatase was upregulated in 420 
many cell types in tissues from achalasic patients, indicating a general increase in 421 
inhibitory signals for cell survival, a mechanism stimulated by Akt-dependent 422 
pathways.
32 
Thus, an INPP4B increased expression can be correlated to the 423 
enrichment in genes involved in cell death. Notably, in achalasia tissues we observed 424 
a decrease in the phosphorylation of the Ser473 in Akt, which is a key 425 
phosphorylation step for its activation and function. Therefore, it may be postulated 426 
that in achalasia the altered molecular signaling led to an overall impaired cell 427 
survival, which, in the long term, generates a permanent tissue damage. Thus, one can 428 
assume that also ICCs, in addition to neurons, can be affected. Since many studies 429 































































have investigated the Akt / INPP4B pathway as a potential “druggable” route to block 430 
tumor proliferation,
33,34
 the development of ad hoc molecules may become relevant 431 
for patients with primary achalasia.  432 
 433 
In conclusion, our study highlights the altered expression of two distinct genes, i.e. c-434 
KIT and INPP4B down- and up-regulation, in patients with primary achalasia. Our 435 
results may provide a basis for future research aimed at investigating novel 436 
therapeutic targets for patients with primary achalasia. 437 
 438 
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Table 1. Genes differentially expressed in achalasia. 532 
Genes overexpressed in achalasia are labeled in red. Green shadowed area indicates 533 










ENST00000451137 CYR61 -2.99 9.71E-06 
ENST00000367976 CTGF -2.74 1.19E-05 
ENST00000513000 INPP4B 1.63 1.42E-04 
ENST00000288135 KIT -1.48 4.17E-04 
ENST00000249075 LIF -2.40 4.23E-04 
ENST00000239938 EGR1 -1.95 4.65E-04 
ENST00000228434 CD69 -3.84 4.94E-04 
ENST00000280979 AKAP6 1.63 7.28E-04 
ENST00000296464 HSPA4L 1.07 8.99E-04 
ENST00000319653 FMN2 2.03 1.11E-03 
ENST00000517956 FBXO32 1.26 1.12E-03 
ENST00000265634 NPTX2 -1.88 1.20E-03 
ENST00000550683 ACVRL1 -1.14 1.25E-03 
ENST00000378827 BMP2 -1.99 1.51E-03 
ENST00000371852 CH25H -3.06 1.56E-03 
ENST00000284669 KLHL41 2.43 1.58E-03 
ENST00000436924 BRE 2.70 1.60E-03 
ENST00000561981 FRRS1L 1.51 1.62E-03 
ENST00000307792 SEMA3E 1.07 1.66E-03 
ENST00000330871 SOCS3 -2.47 2.07E-03 
ENST00000331569 ZNF703 1.18 2.30E-03 
ENST00000305988 ADRB2 -1.41 2.47E-03 
ENST00000420022 ADM5 -1.80 2.58E-03 
ENST00000297316 SOX17 -1.82 2.76E-03 
ENST00000252590 PLVAP -1.29 2.77E-03 
ENST00000256103 PMP2 -2.28 2.87E-03 
ENST00000329099 FAM101B -1.32 3.11E-03 
ENST00000287814 TIMP4 -1.25 3.12E-03 
ENST00000300177 GREM1 -2.58 3.29E-03 
ENST00000485685 GGNBP2 -1.78 3.40E-03 
ENST00000365328 RN7SK -1.61 3.41E-03 
ENST00000284878 CXADR 2.20 3.47E-03 
ENST00000296046 CPA3 -1.76 3.52E-03 
ENST00000302754 JUNB -1.73 3.74E-03 
ENST00000437551 PAX8-AS1 1.36 3.74E-03 
ENST00000322507 COL12A1 -1.10 3.80E-03 
ENST00000307637 C3AR1 -1.86 3.82E-03 
ENST00000340695 SCXA 2.40 3.88E-03 
ENST00000322954 UACA 0.94 3.89E-03 































































ENST00000055682 KIAA2022 1.00 3.92E-03 
ENST00000379374 PHEX -3.10 3.98E-03 
ENST00000357949 SERTAD1 -1.45 4.02E-03 
ENST00000230990 HBEGF -2.36 4.08E-03 
ENST00000359534 KCNK5 -2.25 4.16E-03 
ENST00000224605 GDF10 -1.64 4.17E-03 
ENST00000396184 PDE1C 1.02 4.32E-03 
ENST00000373509 PIM1 -2.29 4.33E-03 
ENST00000408965 CEBPD -1.45 4.59E-03 
ENST00000267984 MESDC1 -1.17 4.82E-03 
ENST00000329608 CSF1 -1.16 4.92E-03 
ENST00000344120 SPRY4 -1.18 5.13E-03 
ENST00000395076 PPM1A 0.85 5.16E-03 
ENST00000350896 MSR1 -1.37 5.21E-03 
ENST00000366667 AGT -1.68 5.22E-03 
ENST00000263370 ITPKC -1.75 5.24E-03 
ENST00000259989 FGFBP2 -1.75 5.24E-03 
ENST00000311922 TRIB1 -2.74 5.24E-03 
ENST00000608521 MIR663A 2.80 5.25E-03 
ENST00000377103 THBD -2.31 5.27E-03 
ENST00000422542 AC005682,5 -1.34 5.32E-03 
ENST00000396037 ST8SIA1 1.75 5.39E-03 
ENST00000264805 PDE5A 2.61 5.58E-03 
ENST00000400546 NCAM2 -1.27 5.65E-03 
ENST00000369026 MCL1 -1.16 6.00E-03 
ENST00000515896 RNA5-8SP6 1.12 6.20E-03 
ENST00000399799 ROCK1 0.96 6.23E-03 
ENST00000273153 CSRNP1 -1.74 6.25E-03 
ENST00000244221 PAIP2B 1.09 6.25E-03 
ENST00000376414 GPR183 -1.77 6.40E-03 
ENST00000500741 DYNLL1-AS1 1.16 6.57E-03 
ENST00000308086 THAP2 0.91 6.67E-03 
ENST00000274063 SFRP2 -1.92 6.68E-03 
ENST00000290551 BTG2 -1.53 6.72E-03 
ENST00000380392 C2CD4B -2.57 6.78E-03 
ENST00000410087 CERKL -1.36 6.83E-03 
ENST00000367558 RGS16 -2.28 7.09E-03 
ENST00000256257 RNF122 -1.65 7.10E-03 
ENST00000367511 FAM129A 0.64 7.12E-03 
ENST00000592790 VMP1 -2.93 7.17E-03 
ENST00000323040 GPR4 -1.97 7.27E-03 
ENST00000307851 HAVCR2 -1.68 7.40E-03 
ENST00000324559 ANO5 0.96 7.62E-03 
ENST00000328041 SLC24A3 -1.35 7.63E-03 
ENST00000311734 IL1RL1 -3.50 7.72E-03 
ENST00000373313 MAFB -1.65 8.05E-03 































































ENST00000382723 MSX1 -2.11 8.32E-03 
ENST00000379731 B4GALT1 -1.49 8.33E-03 
ENST00000329399 PDLIM1 -1.46 8.42E-03 
ENST00000369583 DUSP5 -1.58 8.43E-03 
ENST00000332029 SOCS1 -1.69 8.47E-03 
ENST00000441535 FMO2 -1.27 8.55E-03 
ENST00000256951 EMP1 -2.33 8.71E-03 
ENST00000239223 DUSP1 -1.08 8.75E-03 
ENST00000330106 CEND1 -2.85 8.84E-03 
ENST00000498165 PPM1L 1.08 8.87E-03 
ENST00000506002 MTND6P4 1.03 8.91E-03 
ENST00000244050 SNAI1 -1.59 8.93E-03 
ENST00000380874 FOXC1 -1.77 8.94E-03 
ENST00000396073 ENAM 2.83 9.03E-03 
ENST00000272928 ACKR3 -1.31 9.04E-03 
ENST00000379359 RGCC -1.11 9.22E-03 
ENST00000333926 CISD1 0.80 9.30E-03 
ENST00000367996 ADAMTS4 -4.18 9.37E-03 
ENST00000380079 STEAP4 -2.07 9.38E-03 
ENST00000413366 PRKCA 1.03 9.39E-03 
ENST00000215794 USP18 -1.45 9.57E-03 
ENST00000305352 S1PR1 -1.27 9.74E-03 
ENST00000306065 ANKRD27 0.67 9.81E-03 
ENST00000222390 HGF -2.02 9.83E-03 
ENST00000358432 EPHA2 -1.13 9.85E-03 
ENST00000270001 ZFP14 0.88 9.89E-03 
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Table 2. Output of PANTHER Over-representation test of biological processes 537 
enriched for the genes differentially expressed in achalasia tissues, compared to H. 538 
sapiens gene PANTHER database. 539 
 540 













Protein phosphorylation 81 4 .42 9.53 + 9.80e-04 3.99e-02 




1071 17 5.55 3.06 + 4.05e-05 4.94e-03 
• signal 
transduction 
2318 24 12.01 2.00 + 1.01e-03 3.54e-02 
• Cell 
communication 
2686 26 13.91 1.87 + 1.39e-03 3.76e-02 
Regulation of catalytic 
activity 
359 9 1.86 4.84 + 1.22e-04 7.47e-03 
• regulation of 
molecular 
function 
441 9 2.28 3.94 + 5.38e-04 2.62e-02 
Regulation of phosphate 
metabolic process 
537 12 2.78 4.31 + 2.64e-05 6.44e-03 
Developmental process 1501 18 7.78 2.32 + 1.03e-03 3.13e-02 
 541 
 Only results with False Discovery Rate<0.05 are reported in the table. 542 
 543 
Table 3: Output of STRING (protein-protein interaction and biological processes) for 544 
genes differentially regulated from whole transcriptome analysis of achalasia tissues. 545 
 546 
 
Pathway ID and description Count in 
gene set 




GO 0051094 positive regulation of 
developmental process 
29 1.97e-10 
GO 1901342 regulation of vascular 
development 
15 8.62e-10 
GO 0045597 positive regulation of cell 
differentiation 
24 1.44e-09 
GO 004565 regulation of angiogenesis 14 2.7e-09 





GO 0001228 transcriptional activator activity, 
RNA polymerase II transcription regulatory 
region sequence-specific binding 
9 0.0483 
GO 0005515 protein binding 40 0.0483 
GO 0008083 growth factor activity 3 0.0483 
Cellular component 
(GO) 
GO 005615 extracellular space 20 0.00342 
GO 0009986 cell surface 14 0.00552 
 547 
Statistical background selected for the enrichment analysis set to “whole genome”. 548 
Figure Legends 549 
































































Figure 1. Differentially expressed genes in achalasia tissue. (A) Heat map showing 551 
the concordant differential expression observed in the tissues from achalasia patients 552 
compared to controls (for the genes reported in Table 1). Elaborated with MeV v4.8.1. 553 
(B) Biological processes of genes (GO-Slim Biological processes) differentially 554 
expressed in achalasia, as identified by PANTHER Functional Classification analysis. 555 
(C) Graphical output of significantly enriched protein-protein interactions determined 556 
with STRING analysis, showing the results of the 104 out of 111 dysregulated genes 557 
in achalasia, compared with data present in the STRING databases. The different 558 
colors in the figure inset identify the evidence for the different interactions (known; 559 
predicted; identified with other means, such as co-expression, data mining, and 560 
protein homology). The red square indicates c-KIT. (D) Real-time qRT-PCR data for 561 
c-KIT and INPP4B. Data from case and control tissue biopsies were normalized on a 562 
commercial pool of control tissue biopsies from esophagus. Student’s t-test was 563 
performed and P values are indicated. Bars indicate standard deviations. 564 
 565 
Figure 2. Western blot analysis of differentially expressed genes. (A) Example of 566 
the protein expression profiles in achalasia tissues compared to control samples for c-567 
KIT and INPP4B. Western blotting was repeated in at least two independent 568 
experiments. (B) Densitometric analysis of the relative intensities for c-KIT and 569 
INPP4B. Quantitative data (mean values ± standard deviation) from different 570 
experiments obtained from each individual were compared using Student’s t-test for 571 
statistical analysis. For each sample, densitometric values were normalized on 572 
reference protein (vinculin). All experiments were carried out at least twice. Bars 573 
indicated standard deviations. P values are indicated in the graphs. 574 
































































Figure 3. Immunostaining for c-KIT (A) and INPP4B (B). (A) Examples of the 576 
expression pattern for c-KIT in tissue biopsies from control (left) and achalasia 577 
patients (right). Arrows indicate the positive staining for c-KIT.  c-KIT staining color 578 
histograms of controls (n=6) and cases (n=18) represent the number of samples 579 
assessed according to the semi-quantitative score. c-KIT immunolabeling differences 580 
in cases vs. controls were assessed by Fisher’s exact test. (B) Examples of the 581 
expression pattern for INPP4B in tissue biopsies from control (left) and achalasia 582 
patients (right). INPP4B staining color histograms of controls (n=6) and cases (n=22) 583 
represent the number of samples assessed according to the semi-quantitative score. 584 
INPP4B immunolabeling differences in cases vs. controls were assessed by Fisher’s 585 
exact test. Scale bars are 100µm as indicated. 586 
 587 
Figure 4. Phospho-Akt is down regulated in achalasia. (A) Example of the protein 588 
expression profiles in achalasia tissues compared to control samples of phospho-Akt 589 
(Ser473; Thr308) and total Akt. (B) Quantitative data (mean values ± standard 590 
deviation) from different experiments (performed in duplicate) obtained from each 591 
individual were compared using Student’s t-test. For each sample, densitometric 592 
values were normalized on reference protein (β-actin). The significantly different 593 
relative phospho-Akt (Ser473) levels comparing achalasia vs. control tissues, were 594 
reported in the histogram (P=0.0495, Student’s t-test). Bars indicate standard 595 
deviations.  596 
 597 


































































INPP4B overexpression and c-KIT downregulation in human 4 
achalasia  5 
 6 
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Key points 63 
• Primary achalasia is a disorder due to neuronal defects supplying the 64 
esophagus leading to altered peristalsis and lack of sphincter relaxation. 65 
Nonetheless, the molecular mechanisms involved in this condition are poorly 66 
understood. 67 
 68 
• Transcriptomic analysis of achalasic tissues identified a dysregulated 69 
expression of different genes, in particular c-KIT (downregulated) and 70 
INPP4B (upregulated), the latter being linked to Akt pathway regulation. 71 
 72 
• Our results unravel novel signaling pathways involved in the neuronal and 73 
interstitial cells of Cajal abnormalities in primary achalasia. 74 





































































Background & Aims: Achalasia is a rare motility disorder characterized by myenteric 81 
neuron and interstitial cells of Cajal (ICC) abnormalities leading to deranged/absent 82 
peristalsis and lack of relaxation of the lower esophageal sphincter. The mechanisms 83 
contributing to neuronal and ICC changes in achalasia are only partially understood. 84 
Our goal was to identify novel molecular features occurring in patients with primary 85 
achalasia. 86 
Methods: Esophageal full-thickness biopsies from 42 (22 females; age range: 16-82 87 
yrs) clinically, radiologically and manometrically characterized patients with primary 88 
achalasia were examined and compared to those obtained from ten subjects (controls) 89 
undergoing surgery for uncomplicated esophageal cancer (or upper stomach 90 
disorders). Tissue RNA extracted from biopsies of cases and controls was used for 91 
library preparation and sequencing. Data analysis was performed with the 'edgeR' 92 
option of R-Bioconductor. Data were validated by real-time RT-PCR, western 93 
blotting and immunohistochemistry. 94 
Key Results: Quantitative transcriptome evaluation and cluster analysis revealed 111 95 
differentially expressed genes, with a P≤10
-3
. Nine genes with a P≤10
-4
 were further 96 
validated. CYR61, CTGF, c-KIT, DUSP5, EGR1 were downregulated, whereas 97 
AKAP6 and INPP4B were upregulated in patients vs controls. Compared to controls, 98 
immunohistochemical analysis revealed a clear increase in INPP4B, whereas c-KIT 99 
immunolabeling resulted downregulated. Since INPP4B regulates Akt pathway, we 100 
used western blot to show that phospho-Akt was significantly reduced in achalasia 101 
patients vs controls. 102 































































Conclusions & Inferences: The identification of altered gene expression, including 103 
INPP4B, a regulator of the Akt pathway, highlights novel signaling pathways 104 
involved in the neuronal and ICC changes underlying primary achalasia. 105 
 106 
Key words: Achalasia, cell signaling, c-KIT, INPP4B, transcriptome. 107 
108 































































Introduction  109 
Achalasia is a primary motility disorder of the esophagus occurring at any age, with 110 
an estimated annual incidence of approximately 0.03-1 per 100 people and affecting 111 
both sexes equally.
1,2
 Achalasia can be classified into primary forms (mostly 112 
idiopathic), and cases associated with systemic disorders.
3,4
 From a pathogenetic 113 
stand-point, achalasia is characterized by a predominant loss of inhibitory myenteric 114 
neurons with a relative increase of cholinergic motorneurons
5
. Progressively 115 
degenerative processes may involve virtually all neurons over time. These neuronal 116 
changes result in an increase of the lower esophageal sphincter (LES) tone, which, in 117 
conjunction with an altered peristalsis of the esophageal body, represent the 118 
manometric correlate of any form of achalasia.
6
 Because of these functional 119 
abnormalities patients with achalasia complain of dysphagia, regurgitation and chest 120 
pain, often severe enough to require either surgery or pneumatic dilatation
7
. 121 
Mechanisms leading to esophageal myenteric neurodegeneration and loss include 122 
autoimmune responses likely triggered by environmental factors (e.g., neurotropic 123 
viruses) in genetically predisposed individuals.
2,3,8
 In addition to neurons, 124 
abnormalities of interstitial cells of Cajal (ICC), the pace-maker cells of the 125 




The current standard for diagnosing achalasia is high-resolution manometry, although 128 
molecular biomarkers would be useful not only for diagnostic purposes, but also to 129 
address targeted therapeutic options so far not yet available. Proteomic analysis of 130 
sera from patients with achalasia and healthy individuals showed disease-related 131 
upregulation of transthyretin (TTR), a carrier of thyroid hormone thyroxine and a 132 
retinol-binding protein, associated with familial amyloid polyneuropathy.
10
 The 133 































































observed upregulation may correlate with the consequent neural degeneration 134 
observed in achalasic patients.
11
 Other studies demonstrated increased deposits of the 135 




Achalasia due to rare genetic abnormalities includes recessive forms with mutations 138 
in the neuronal nitric oxide synthase gene, NOS1
13
, or in ALADIN gene
14
 (Allgrove 139 
syndrome or triple A syndrome, characterized by alacrima, achalasia and adrenal 140 
cortex failure; OMIM #231550). Genome-wide and candidate gene association 141 
studies have implicated the human leukocyte antigen (HLA) class II system as the 142 
underlying genetic predisposing factor in achalasia. In particular, an 8-residues 143 
insertion in the cytoplasmic tail of HLA-DQβ1 has been identified as a strong risk 144 
factor for achalasia, with a specific geospatial north-south gradient among 145 
Europeans.
15
 Two amino acid substitutions in the extracellular domain of HLA-146 
DQα1, (lysine 41 encoded by HLA-DQA1*01:03) and of HLA-DQβ1, (glutamic acid 147 
45, encoded by HLA-DQB1*03:01 and HLA-DQB1*03:04) were characterized as 148 
independent risk factors for achalasia and patients with the DQA1*0103 and 149 




Nevertheless, the mechanisms contributing to the observed neuronal and ICC changes 152 
in achalasia are still partially understood. The aim of this study was to identify the 153 
dysregulated molecular pathways / events occurring in primary (idiopathic) achalasia 154 
to provide a molecular signature of primary achalasia. 155 
 156 
Materials and Methods 157 
Patients and tissue biopsies 158 































































A number of 42 (n= 20 from Italy; n= 22 from Belgium; 22 females; age range: 16-82 159 
yrs) patients with a well-established clinical, radiological and manometric diagnosis 160 
of primary achalasia were recruited (Supplementary Table 1A). The included patients 161 
were all of Caucasian origin. Each patient underwent surgery and 1-2 tissue samples 162 
were obtained via a laparoscopic extramucosal Heller’s myotomy extended 4-5 cm 163 
along the distal esophagus (i.e., 1-2 cm full-thickness biopsy containing the circular 164 
and longitudinal muscle with the associated enteric nervous system). Comparable 165 
control tissues were obtained from the corresponding esophageal region of 10 (3 166 
females; age range: 45-87 yrs) controls, who were referred to surgery for 167 
uncomplicated esophageal cancer and upper stomach disorders, as reported in 168 
Supplementary Table 1B. Margins of all of sampled tissues were free of cancer. 169 
Signed informed consent was obtained for each subject enrolled in the study and data 170 
handling was performed according to the Helsinki declaration. The study was 171 
approved by the local Ethic Committee (study 42/2011/0/Oss protocol #877/211). 172 
RNA extraction 173 
Total RNA was extracted with the RiboPure kit from fresh frozen biopsies stored at -174 
80°C in RNAlater, according to the manufacturer’s instruction (Ambion, 175 
ThermoFisher Scientific, Waltham, MA, USA). RNA was resuspended in 40 µl of 176 
RNase-free water, and quality and quantity of RNA were evaluated on Agilent 177 
Bioanalyzer 2100 instrument (Agilent, Santa Clara, CA, USA). 150 ng of RNA was 178 
used for each library preparation, according to the TruSeq RNA Sample Prep v2 179 
protocol (Illumina, San Diego, CA, USA). Poly(A)-RNA molecules from 500 ng of 180 
total RNA were purified using oligo-dT magnetic beads. Following purification, the 181 
mRNA was fragmented and randomly primed for reverse transcription followed by 182 
second-strand synthesis to create double-stranded cDNA fragments, that were then 183 































































end-repaired and ligated using paired-end sequencing adapters. The products were 184 
then amplified to enrich for fragments carrying adapters ligated on both ends, thus 185 
creating the final cDNA library. RNAseq was performed on the HiScan SQ platform 186 
(Illumina) as 75 bp paired-end. 187 
RNAseq data analysis 188 
Raw paired-end reads obtained by the HiScan SQ were filtered and trimmed with the 189 
tool AdapterRemoval (http://code.google.com/p/adapterremoval/) to exclude low 190 
quality bases and sequence adapters. Short reads were mapped on human reference 191 
genome hg19 (https://genome.ucsc.edu/) with the pipeline Bowtie/Tophat 192 
(http://ccb.jhu.edu/software/tophat/index.shtml) and Samtools 193 
(http://samtools.sourceforge.net/) was adopted to remove optical/PCR duplicates. 194 
Gene expression quantification was performed with the Python package htseq-count 195 
(http://www-huber.embl.de/HTSeq/doc/overview.html) using the Ensembl release 72 196 
annotation features (http://www.ensembl.org). The raw counts were normalized with 197 
the R-Bioconductor package edger (function calcNormFactors) as “count per million” 198 
(cpm). A filter procedure was adopted to analyze only genes with cpm > 3 in at least 199 
2/4 samples. This process allowed to include 9616 genes, that were analyzed with the 200 
R-Bioconductor package limma to determine the differentially expressed genes. In 201 
particular, the function lmFit was used to fit the linear model, and the function eBayes 202 
was adopted to compute the moderate t-statistic. Genes were ranked in order of 203 
evidence for differential expression using log2 fold change (log2FC) and P value.
21
 204 
Multiple Experiment Viewer (MEV) (v4.8.1) was used to perform the analysis in two 205 
different ways: unsupervised hierarchical clustering (distance: Manhattan; clustering 206 
method: average) and principal component analysis. A total of 111 differentially 207 
expressed genes were selected (P≤ 10
-3
) for the evaluation of the functional 208 































































classification of biological processes and pathway over-representation, performed 209 
with the analytical tools PANTHER13.1 (Protein ANalysis THrough Evolutionary 210 
Relationships; http://pantherdb.org) and STRING. PANTHER is tightly integrated 211 
with a number of different genomic resources: the InterPro Consortium of protein 212 
classification resources, the Quest for Orthologs Consortium and the UniProt 213 
Reference Proteome data sets. PANTHER Over-representation tool includes 214 
functional annotations directly downloaded from the Gene Ontology (GO) 215 
Consortium, in addition to the phylogenetically inferred annotations.
22
 Analysis was 216 
performed using the option PANTHER Functional Classification and Over-217 
representation Tests, using the PANTHER GO-Slim Biological process and the 218 
Fisher's Exact with false discovery rate (FDR) multiple test correction for statistical 219 
analysis. Independent analysis to observe protein-protein interaction was performed 220 
with STRING, a database of known and predicted protein-protein interactions. The 221 
interactions include direct (physical) and indirect (functional) associations; stemming 222 
from computational prediction, from knowledge transfer between organisms, and 223 
from interactions aggregated from other (primary) databases.
23,24
 224 
Quantitative real-time RT-qPCR 225 
DNase I-treated RNA (200 ng) was used for reverse transcription (RT) with random 226 
hexamers using the Multiscribe RT system (ThermoFisher Scientific) at 48°C for 40 227 
min in a final volume of 50 µl. DNase I-treated total RNA was obtained from a pool 228 
of commercially available fresh frozen tissue biopsies of five controls subjects (single 229 
vial purchased from AMSBIO, Abingdon, Oxford, UK; reference code: R1234106-P, 230 
lot number B209050, human normal adult esophageal total RNA); the other RNAs 231 
were obtained from fresh frozen tissue biopsies as described above. 232 































































RT-qPCR was performed with SYBRGreen, 0.5 µM primers, in an ABI 7500 Real-233 
Time PCR System (ThermoFisher Scientific). All target genes were normalized with 234 
the endogenous control (beta-actin) using the ∆∆Ct comparative method. Primers are 235 
available from the Authors on request. 236 
Western blotting 237 
Proteins were extracted from fresh frozen tissue biopsies of esophagus of achalasia 238 
patients and controls by sonication using the Diagenode Bioruptor Pico sonicator 239 
System (V 1.1) (10 cycles of 30 on/30 off; 20-60 kHz), in a volume of 50 µl of Laemli 240 
buffer 1X. A pool of normal esophageal tissues was commercially available (Abcam, 241 
Cambridge, UK, reference code ab30243 - Human esophagus normal tissue lysate - 242 
total protein), the other tissues analyzed with western blotting were obtained from 243 
fresh frozen tissue biopsies of single cases and controls as reported in Supplementary 244 
Tables 1A and 1B. Proteins were visualized on Coomassie Blue gel for quality and 245 
quantity control. Western blot analysis was performed by SDS gel electrophoresis and 246 
transfer onto nitrocellulose membrane, using the TransBlot system (Bio-Rad 247 
Laboratories, Segrate, Italy). Primary antibodies used were the following: rabbit anti-248 
INPP4B diluted 1:200 (Abcam); rabbit anti-c-KIT (Abcam) diluted 1:200; mouse 249 
anti-vinculin (Sigma-Aldrich, St. Louis, MO, USA) diluted at 1:5000; mouse anti-250 
GAPDH 1:10000 (Abcam); anti p-Akt (Ser473), anti p-Akt (Thr308), anti Akt (Cell 251 
Signaling, Leiden, Netherlands), anti β-actin 1:10000 (Sigma-Aldrich). HRPO-252 
conjugated secondary antibodies (Sigma-Aldrich) were diluted 1:35000 in blocking 253 
solution. Bands were visualized by the ECL method Supernova (Cyanagen, Bologna, 254 
Italy) using the Chemidoc XRS+ Imager and densitometric analysis was performed 255 
with Image lab Software (Bio-Rad Laboratories). All western blot analyses were 256 































































performed at least in duplicate for each protein extract from each patient and control 257 
tissue biopsy.  258 
Immunohistochemistry 259 
Immunohistochemistry was performed on paraffin-embedded adult human esophagus 260 
tissues according to protocols validated in our laboratory.
25
 Immunohistochemistry 261 
analyses and image acquisitions were performed in our laboratory at the University of 262 
Bologna. Briefly, tissue sections were treated to remove paraffin embedding by 263 
sequential washes in xylene and graded ethanol. Antigen unmasking was performed 264 
by heating sections at 95°C in 10 mM Sodium citrate buffer, pH 6.0, for 10 min and 265 
subsequent cooling at room temperature for 30 min. To reduce endogenous 266 
peroxidases, tissue sections were treated with an ad hoc blocking kit (GeneTex Inc., 267 
Irvine, CA, USA) and incubated for 16 h at 4°C with the same primary antibodies 268 
used for western blotting, but diluted 1:50. 3,3'-diaminobenzidine staining was 269 
performed according to standard protocols (DAB500 IHC Select® kit, Merck 270 
Millipore, Darmstadt, Germany). Scores were assigned based on the intensity of DAB 271 
staining (0 = no staining; + = 10-50% staining; ++ = 50-90% staining; +++ = ≥90% 272 
staining of the areas; all images were acquired at 10x magnification) according to 273 
standard pathological assessment.
26
 Three expert observers independently evaluated 274 
the images (E.B., F.B. and R. De G.), and their analyses were blinded regarding 275 
control vs. achalasia state. Image capturing of achalasia and control tissues was 276 
performed on a Nikon microscope using DS-5M digital camera (Nikon Instruments, 277 
Düsseldorf, Germany).  278 
 279 
Statistical analysis 280 































































Quantitative difference in densitometry of western blots was performed with the 281 
Student’s t-test option of GraphPad Quickstat calculator; statistical differences for the 282 
scores assigned to IHC samples from tissue biopsies was performed with Fisher’s 283 
Test (4 x 2 contingency table) using the program Vassarstats. 284 
 285 
Results 286 
Whole transcriptome analysis via RNAseq 287 
Total RNA extracted from esophageal biopsies of four cases (2F; age range: 30-58 288 
yrs) and four controls (3F; age range: 27-50 yrs) was used for library preparation and 289 
sequencing on Illumina HiScan SQ platform. Raw data showing the total amount of 290 
reads/library and the mean coverage are reported in Supplementary Table 2, along 291 
with the mean coverage for each sample. Quantitative data analysis using 292 
Bioconductor from R package identified 111 genes with differential expression 293 
between cases and controls at a P≤ 10
-3
 (Table 1). Compared to controls, 77 genes 294 
were downregulated and 34 genes were upregulated in the achalasia group. 295 
Hierarchical clustering considering the 111 genes was performed using MEV v4.8.1. 296 
As shown in the heat map in Figure 1A, a concordant signature of up- and down-297 
regulation expression was evident between cases and controls. Analysis using 298 
PANTHER Functional classification test (PANTHER GO Slim Process) led us to 299 
functionally map a total of 109 out of the 111 differentially expressed genes to 300 
different biological processes, including, amongst others, cell adhesion, biogenesis, 301 
developmental, immune and metabolic processes and response to stimuli 302 
(http://www.pantherdb.org/chart/pantherChart.jsp?listType=1&filterLevel=1&type=2303 
&chartType=1&save=yes&basketItems=all&zoom=1.25&trackingId=4DCA8C9D00304 
F5C4649E3257CE82CFAC3E) (Figure 1B). PANTHER Over-representation Test 305 































































analysis was performed against the H. sapiens gene database, showing a set of over-306 
represented biological processes in achalasia, including, amongst others, 307 
phosphorylation, the MAPK cascade signaling (including intracellular signal 308 
transduction and cell communication), regulation of phosphate metabolism and 309 
developmental processes, e.g. cell differentiation and death (FDR< 0.05; Table 2).  310 
Network analysis was performed with STRING using the list of genes (the previously 311 
identified 111 genes) reported in Table 1, using the H. sapiens database as model 312 
organism, and the “whole genome” option as statistical background. A number of 104 313 
out of 111 genes matched the STRING protein database and were included in the 314 
analysis (https://string-db.org/cgi/network.pl?taskId=u9O5yLo4Lf2G). Several 315 
pathways were identified that showed a functional enrichment for biological 316 
processes, such as regulation of development, cell differentiation, angiogenesis and 317 
vascular architecture, with significant P values reported in Table 3. Many protein-318 
protein interactions converged on c-KIT (Figure 1C). 319 
Among the dysregulated genes in achalasia, those differentially expressed with a 320 
significant P≤ 10
-4
 were selected for further investigation, including CYR61, CTGF, 321 
c-KIT, EGR1, LIF and CD69 (downregulated); and AKAP6, and INPP4B 322 
(overexpressed) (Table 1). To validate the data from whole transcriptome analysis, we 323 
performed quantitative real-time RT-qPCR using the total RNA of already sequenced 324 
samples (including two patients and one control). For each real-time RT-qPCR, raw 325 
data were normalized on a commercial pool of human normal esophagus RNA from 326 
fresh frozen tissue biopsies of five individuals (AMSBIO), using the ∆∆Ct method. 327 
Data reported in Figure 1D show independent technical replicates (same case-control 328 
samples, independent retro-transcription and real-time processes). A significant 329 
dysregulation of expression was confirmed for c-KIT and INPP4B (Figure 1D). These 330 































































findings prompted us to focus on these two molecular targets, i.e. c-KIT and INPP4B, 331 
which were down- and up-regulated, respectively. 332 
 333 
Protein analysis of INPP4B and c-KIT confirmed the RNAseq data 334 
The protein expression of c-KIT and INPP4B was studied by western blotting. In 335 
these experiments, control samples included a pool of normal esophageal tissues 336 
(Abcam) from five subjects in addition to control tissues obtained from single 337 
individual control subjects. Western blotting analysis for each tissue lysate was 338 
performed at least in two independent experiments, i.e. technical replicates. Equal 339 
amount of proteins was loaded for each sample and intensities were normalized using 340 
reference proteins. Representative examples of the protein patterns observed for c-341 
KIT, INPP4B and reference proteins were reported in Figure 2A. Densitometric 342 
analysis of western blots was performed as indicated in Figure 2B. All cases and 343 
controls included in the western blotting analysis were reported in Supplementary 344 
Tables 1A and 1B. c-KIT downregulation was confirmed in tissue biopsies of 345 
achalasia patients compared to controls (P= 0.0003, Student’s t-test; Figure 2B), 346 
whereas INPP4B overexpression was significantly detectable in achalasia patients vs. 347 
controls (P=0.0381; Student’s t-test, Figure 2B). 348 
Immunohistochemistry analysis was performed in order to confirm the western blot 349 
data and to determine the cellular localization of the proteins herein identified by 350 
western blot. The density of c-KIT immunoreactive cells (mainly with the typical 351 
shape of ICC) was lower in achalasia than in controls (Fisher’s exact test, P= 0.0005, 352 
Figure 3A). Compared to controls, INPP4B immunoreactivity was more intense in 353 
achalasia patients. In INPP4B-positive cases, the immunoreactive signal was present 354 
in different cells including muscle cells and myenteric ganglia. INPP4B expression in 355 































































the normal tissues was very low or virtually absent (Fisher’s exact test, P= 0.0023; 356 
Figure 3B). 357 
 358 
Phospho-Akt is down regulated in achalasia 359 
As INPP4B is a negative regulator of Akt signaling, we investigated Akt 360 
phosphorylation status. Equal amount of proteins was loaded for each sample and 361 
intensities were normalized using reference proteins. Representative examples of the 362 
phosphorylation patterns observed for the two phosphorylation sites in Akt (Ser473, 363 
and Thr308) were reported in Figure 4A. Densitometric analysis, performed 364 
according to our previously published data,
27
 revealed that tissue samples from 365 
achalasia patients presented a reduced Akt phosphorylation, in particular the 366 
phosphorylation at Ser473 was significantly decreased compared to control tissues 367 
(P=0.0495, Student’s t-test; Figure 4B). 368 
 369 
Discussion 370 
Primary achalasia causes significant impairment of esophageal motility leading to 371 
symptom generation and overall reduced patients’ quality of life. This esophageal 372 
dysmotility of the esophagus has a complex etio-pathogenesis. Recent findings 373 
indicate that both an inflammatory / immune-mediated insult, as exhibited by 374 
myenteric ganglionitis (likely driven by neurotropic, e.g. herpes, virus infection)
28
 and 375 
circulating anti-neuronal antibodies, play a pathogenetic role. A genetic predisposition 376 
conferred by HLA genetic background
20
 can contribute to neural abnormalities 377 
underlying achalasia. A predominant genetic component has been identified in well-378 
defined conditions such as ‘triple A’ (also referred to Allgrove’s syndrome), where 379 
mutations in the ALADIN gene
14
 were found in familial clusters. Other data derive 380 































































from NOS1, which encodes for the neuronal nitric oxide synthase. A stop codon 381 
mutation of this gene has been reported in a family where two children manifested a 382 
very severe clinical phenotype dominated by achalasia.
13
 Nevertheless, in the majority 383 
of cases the factors causing achalasia remain to be elucidated. As a consequence, the 384 
available therapeutic approaches are far from targeting the actual mechanisms leading 385 
to the neural impairment recognized to be the primum movens of this severe 386 
esophageal disorder. New understanding of achalasia, involving a deeper knowledge 387 
of the attendant molecular mechanisms, should aim to a better patient management 388 
and stop the disease at early stages. Therefore, the present study attempted to decipher 389 
the altered molecular pathways in patients with achalasia. We strategically used 390 
esophageal tissues from achalasic patients and examined gene expression via whole 391 
transcriptome analysis in order to provide novel targets for a therapeutic approach. 392 
From the RNAseq data we detected 111 genes with an altered expression. Functional 393 
classification and over-representation analysis of the biological processes, where 394 
these genes mapped, was performed with two different bioinformatic tools, 395 
PANTHER and STRING. Results showed a significant over-representation of 396 
phosphorylation processes, intracellular signaling, cell communication and 397 
development /differentiation processes, including cell death. These data suggest that 398 
an imbalance of cell growth/survival vs. cell death may cause the defects observed in 399 
the achalasia tissues, not only in term of neuron loss, but also as an overall tissue 400 
degeneration. Notably, in a recent study, Palmieri et al. performed transcriptome 401 
analysis on tissues of primary achalasia patients and identified a significant 402 
enrichment of neuro-muscular and neuro-immune processes. These data support the 403 
concept that achalasia results from degenerative alterations / loss of myenteric 404 



































































Among the genes with significant dysregulation, we confirmed by real-time qPCR c-407 
KIT downregulation and INPP4B upregulation, respectively. c-KIT significant 408 
downregulation, validated both via western blot and immunohistochemistry, confirms 409 
and expands previously reported data showing a loss of ICC network in tissues of 410 
patients with primary achalasia.
9
 Our data highlighting a significant decrease of c-KIT 411 
expression in human achalasia support the concept that stem cell factor, the major 412 
ligand to c-KIT, cannot mediate ICC maintenance and survival. Although we did not 413 
look into specific apoptotic mechanisms, it is likely that a programmed cell death can 414 
involve ICC in achalasia.
30
 Since ICC play a role in esophageal motility, their 415 




The second gene for which we were able to confirm an altered expression at the 418 
protein level is INPP4B, encoding for inositol polyphosphate-4-phosphatase type II B, 419 
a negative regulator of Akt.
32,33
 The expression of this phosphatase was upregulated in 420 
many cell types in tissues from achalasic patients, indicating a general increase in 421 
inhibitory signals for cell survival, a mechanism stimulated by Akt-dependent 422 
pathways.
32 
Thus, an INPP4B increased expression can be correlated to the 423 
enrichment in genes involved in cell death. Notably, in achalasia tissues we observed 424 
a decrease in the phosphorylation of the Ser473 in Akt, which is a key 425 
phosphorylation step for its activation and function. Therefore, it may be postulated 426 
that in achalasia the altered molecular signaling led to an overall impaired cell 427 
survival, which, in the long term, generates a permanent tissue damage. Thus, one can 428 
assume that also ICCs, in addition to neurons, can be affected. Since many studies 429 































































have investigated the Akt / INPP4B pathway as a potential “druggable” route to block 430 
tumor proliferation,
33,34
 the development of ad hoc molecules may become relevant 431 
for patients with primary achalasia.  432 
 433 
In conclusion, our study highlights the altered expression of two distinct genes, i.e. c-434 
KIT and INPP4B down- and up-regulation, in patients with primary achalasia. Our 435 
results may provide a basis for future research aimed at investigating novel 436 
therapeutic targets for patients with primary achalasia. 437 
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Table 1. Genes differentially expressed in achalasia. 532 
Genes overexpressed in achalasia are labeled in red. Green shadowed area indicates 533 










ENST00000451137 CYR61 -2.99 9.71E-06 
ENST00000367976 CTGF -2.74 1.19E-05 
ENST00000513000 INPP4B 1.63 1.42E-04 
ENST00000288135 KIT -1.48 4.17E-04 
ENST00000249075 LIF -2.40 4.23E-04 
ENST00000239938 EGR1 -1.95 4.65E-04 
ENST00000228434 CD69 -3.84 4.94E-04 
ENST00000280979 AKAP6 1.63 7.28E-04 
ENST00000296464 HSPA4L 1.07 8.99E-04 
ENST00000319653 FMN2 2.03 1.11E-03 
ENST00000517956 FBXO32 1.26 1.12E-03 
ENST00000265634 NPTX2 -1.88 1.20E-03 
ENST00000550683 ACVRL1 -1.14 1.25E-03 
ENST00000378827 BMP2 -1.99 1.51E-03 
ENST00000371852 CH25H -3.06 1.56E-03 
ENST00000284669 KLHL41 2.43 1.58E-03 
ENST00000436924 BRE 2.70 1.60E-03 
ENST00000561981 FRRS1L 1.51 1.62E-03 
ENST00000307792 SEMA3E 1.07 1.66E-03 
ENST00000330871 SOCS3 -2.47 2.07E-03 
ENST00000331569 ZNF703 1.18 2.30E-03 
ENST00000305988 ADRB2 -1.41 2.47E-03 
ENST00000420022 ADM5 -1.80 2.58E-03 
ENST00000297316 SOX17 -1.82 2.76E-03 
ENST00000252590 PLVAP -1.29 2.77E-03 
ENST00000256103 PMP2 -2.28 2.87E-03 
ENST00000329099 FAM101B -1.32 3.11E-03 
ENST00000287814 TIMP4 -1.25 3.12E-03 
ENST00000300177 GREM1 -2.58 3.29E-03 
ENST00000485685 GGNBP2 -1.78 3.40E-03 
ENST00000365328 RN7SK -1.61 3.41E-03 
ENST00000284878 CXADR 2.20 3.47E-03 
ENST00000296046 CPA3 -1.76 3.52E-03 
ENST00000302754 JUNB -1.73 3.74E-03 
ENST00000437551 PAX8-AS1 1.36 3.74E-03 
ENST00000322507 COL12A1 -1.10 3.80E-03 
ENST00000307637 C3AR1 -1.86 3.82E-03 
ENST00000340695 SCXA 2.40 3.88E-03 
ENST00000322954 UACA 0.94 3.89E-03 































































ENST00000055682 KIAA2022 1.00 3.92E-03 
ENST00000379374 PHEX -3.10 3.98E-03 
ENST00000357949 SERTAD1 -1.45 4.02E-03 
ENST00000230990 HBEGF -2.36 4.08E-03 
ENST00000359534 KCNK5 -2.25 4.16E-03 
ENST00000224605 GDF10 -1.64 4.17E-03 
ENST00000396184 PDE1C 1.02 4.32E-03 
ENST00000373509 PIM1 -2.29 4.33E-03 
ENST00000408965 CEBPD -1.45 4.59E-03 
ENST00000267984 MESDC1 -1.17 4.82E-03 
ENST00000329608 CSF1 -1.16 4.92E-03 
ENST00000344120 SPRY4 -1.18 5.13E-03 
ENST00000395076 PPM1A 0.85 5.16E-03 
ENST00000350896 MSR1 -1.37 5.21E-03 
ENST00000366667 AGT -1.68 5.22E-03 
ENST00000263370 ITPKC -1.75 5.24E-03 
ENST00000259989 FGFBP2 -1.75 5.24E-03 
ENST00000311922 TRIB1 -2.74 5.24E-03 
ENST00000608521 MIR663A 2.80 5.25E-03 
ENST00000377103 THBD -2.31 5.27E-03 
ENST00000422542 AC005682,5 -1.34 5.32E-03 
ENST00000396037 ST8SIA1 1.75 5.39E-03 
ENST00000264805 PDE5A 2.61 5.58E-03 
ENST00000400546 NCAM2 -1.27 5.65E-03 
ENST00000369026 MCL1 -1.16 6.00E-03 
ENST00000515896 RNA5-8SP6 1.12 6.20E-03 
ENST00000399799 ROCK1 0.96 6.23E-03 
ENST00000273153 CSRNP1 -1.74 6.25E-03 
ENST00000244221 PAIP2B 1.09 6.25E-03 
ENST00000376414 GPR183 -1.77 6.40E-03 
ENST00000500741 DYNLL1-AS1 1.16 6.57E-03 
ENST00000308086 THAP2 0.91 6.67E-03 
ENST00000274063 SFRP2 -1.92 6.68E-03 
ENST00000290551 BTG2 -1.53 6.72E-03 
ENST00000380392 C2CD4B -2.57 6.78E-03 
ENST00000410087 CERKL -1.36 6.83E-03 
ENST00000367558 RGS16 -2.28 7.09E-03 
ENST00000256257 RNF122 -1.65 7.10E-03 
ENST00000367511 FAM129A 0.64 7.12E-03 
ENST00000592790 VMP1 -2.93 7.17E-03 
ENST00000323040 GPR4 -1.97 7.27E-03 
ENST00000307851 HAVCR2 -1.68 7.40E-03 
ENST00000324559 ANO5 0.96 7.62E-03 
ENST00000328041 SLC24A3 -1.35 7.63E-03 
ENST00000311734 IL1RL1 -3.50 7.72E-03 
ENST00000373313 MAFB -1.65 8.05E-03 































































ENST00000382723 MSX1 -2.11 8.32E-03 
ENST00000379731 B4GALT1 -1.49 8.33E-03 
ENST00000329399 PDLIM1 -1.46 8.42E-03 
ENST00000369583 DUSP5 -1.58 8.43E-03 
ENST00000332029 SOCS1 -1.69 8.47E-03 
ENST00000441535 FMO2 -1.27 8.55E-03 
ENST00000256951 EMP1 -2.33 8.71E-03 
ENST00000239223 DUSP1 -1.08 8.75E-03 
ENST00000330106 CEND1 -2.85 8.84E-03 
ENST00000498165 PPM1L 1.08 8.87E-03 
ENST00000506002 MTND6P4 1.03 8.91E-03 
ENST00000244050 SNAI1 -1.59 8.93E-03 
ENST00000380874 FOXC1 -1.77 8.94E-03 
ENST00000396073 ENAM 2.83 9.03E-03 
ENST00000272928 ACKR3 -1.31 9.04E-03 
ENST00000379359 RGCC -1.11 9.22E-03 
ENST00000333926 CISD1 0.80 9.30E-03 
ENST00000367996 ADAMTS4 -4.18 9.37E-03 
ENST00000380079 STEAP4 -2.07 9.38E-03 
ENST00000413366 PRKCA 1.03 9.39E-03 
ENST00000215794 USP18 -1.45 9.57E-03 
ENST00000305352 S1PR1 -1.27 9.74E-03 
ENST00000306065 ANKRD27 0.67 9.81E-03 
ENST00000222390 HGF -2.02 9.83E-03 
ENST00000358432 EPHA2 -1.13 9.85E-03 
ENST00000270001 ZFP14 0.88 9.89E-03 
 535 
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Table 2. Output of PANTHER Over-representation test of biological processes 537 
enriched for the genes differentially expressed in achalasia tissues, compared to H. 538 
sapiens gene PANTHER database. 539 
 540 













Protein phosphorylation 81 4 .42 9.53 + 9.80e-04 3.99e-02 




1071 17 5.55 3.06 + 4.05e-05 4.94e-03 
• signal 
transduction 
2318 24 12.01 2.00 + 1.01e-03 3.54e-02 
• Cell 
communication 
2686 26 13.91 1.87 + 1.39e-03 3.76e-02 
Regulation of catalytic 
activity 
359 9 1.86 4.84 + 1.22e-04 7.47e-03 
• regulation of 
molecular 
function 
441 9 2.28 3.94 + 5.38e-04 2.62e-02 
Regulation of phosphate 
metabolic process 
537 12 2.78 4.31 + 2.64e-05 6.44e-03 
Developmental process 1501 18 7.78 2.32 + 1.03e-03 3.13e-02 
 541 
 Only results with False Discovery Rate<0.05 are reported in the table. 542 
 543 
Table 3: Output of STRING (protein-protein interaction and biological processes) for 544 
genes differentially regulated from whole transcriptome analysis of achalasia tissues. 545 
 546 
 
Pathway ID and description Count in 
gene set 




GO 0051094 positive regulation of 
developmental process 
29 1.97e-10 
GO 1901342 regulation of vascular 
development 
15 8.62e-10 
GO 0045597 positive regulation of cell 
differentiation 
24 1.44e-09 
GO 004565 regulation of angiogenesis 14 2.7e-09 





GO 0001228 transcriptional activator activity, 
RNA polymerase II transcription regulatory 
region sequence-specific binding 
9 0.0483 
GO 0005515 protein binding 40 0.0483 
GO 0008083 growth factor activity 3 0.0483 
Cellular component 
(GO) 
GO 005615 extracellular space 20 0.00342 
GO 0009986 cell surface 14 0.00552 
 547 
Statistical background selected for the enrichment analysis set to “whole genome”. 548 
Figure Legends 549 
































































Figure 1. Differentially expressed genes in achalasia tissue. (A) Heat map showing 551 
the concordant differential expression observed in the tissues from achalasia patients 552 
compared to controls (for the genes reported in Table 1). Elaborated with MeV v4.8.1. 553 
(B) Biological processes of genes (GO-Slim Biological processes) differentially 554 
expressed in achalasia, as identified by PANTHER Functional Classification analysis. 555 
(C) Graphical output of significantly enriched protein-protein interactions determined 556 
with STRING analysis, showing the results of the 104 out of 111 dysregulated genes 557 
in achalasia, compared with data present in the STRING databases. The different 558 
colors in the figure inset identify the evidence for the different interactions (known; 559 
predicted; identified with other means, such as co-expression, data mining, and 560 
protein homology). The red square indicates c-KIT. (D) Real-time qRT-PCR data for 561 
c-KIT and INPP4B. Data from case and control tissue biopsies were normalized on a 562 
commercial pool of control tissue biopsies from esophagus. Student’s t-test was 563 
performed and P values are indicated. Bars indicate standard deviations. 564 
 565 
Figure 2. Western blot analysis of differentially expressed genes. (A) Example of 566 
the protein expression profiles in achalasia tissues compared to control samples for c-567 
KIT and INPP4B. Western blotting was repeated in at least two independent 568 
experiments. (B) Densitometric analysis of the relative intensities for c-KIT and 569 
INPP4B. Quantitative data (mean values ± standard deviation) from different 570 
experiments obtained from each individual were compared using Student’s t-test for 571 
statistical analysis. For each sample, densitometric values were normalized on 572 
reference protein (vinculin). All experiments were carried out at least twice. Bars 573 
indicated standard deviations. P values are indicated in the graphs. 574 
































































Figure 3. Immunostaining for c-KIT (A) and INPP4B (B). (A) Examples of the 576 
expression pattern for c-KIT in tissue biopsies from control (left) and achalasia 577 
patients (right). Arrows indicate the positive staining for c-KIT. c-KIT staining color 578 
histograms of controls (n=6) and cases (n=18) represent the number of samples 579 
assessed according to the semi-quantitative score. c-KIT immunolabeling differences 580 
in cases vs. controls were assessed by Fisher’s exact test. (B) Examples of the 581 
expression pattern for INPP4B in tissue biopsies from control (left) and achalasia 582 
patients (right). INPP4B staining color histograms of controls (n=6) and cases (n=22) 583 
represent the number of samples assessed according to the semi-quantitative score. 584 
INPP4B immunolabeling differences in cases vs. controls were assessed by Fisher’s 585 
exact test. Scale bars are 100µm as indicated. 586 
 587 
Figure 4. Phospho-Akt is down regulated in achalasia. (A) Example of the protein 588 
expression profiles in achalasia tissues compared to control samples of phospho-Akt 589 
(Ser473; Thr308) and total Akt. (B) Quantitative data (mean values ± standard 590 
deviation) from different experiments (performed in duplicate) obtained from each 591 
individual were compared using Student’s t-test. For each sample, densitometric 592 
values were normalized on reference protein (β-actin). The significantly different 593 
relative phospho-Akt (Ser473) levels comparing achalasia vs. control tissues, were 594 
reported in the histogram (P=0.0495, Student’s t-test). Bars indicate standard 595 
deviations.  596 
 597 
































































Supplementary Table 1: Clinical and epidemiological data of achalasia patients (a) and 
controls (b) 
a) Achalasia 
ACHA pts ID Sex Age 
Age at 
diagnosis 
LES basal pressure 
(mm Hg) 
Duration of symptoms before 
diagnosis(yrs) Type of molecular analysis 
ITA_ACHA77 M 43 30 15 15 wb 
ITA_ACHA69 M 84 83 53 20 wb 
ITA_ACHA74 M 42 41 22.5 5 wb 
ITA_ACHA59 F 51 50 20 3 wb/IHC 
ITA_ACHA81 F 24 20 18 5 wb 
ITA_ACHA40 F 42 39 28 8 wb 
ITA_ACHA17 F 46 45 20 10 wb 
ITA_ACHA76 M 55 54 24 10 wb 
ITA_ACHA71 F 72 70 15 8 wb 
ITA_ACHA34 M 68 67 44 8 RNAseq 
ITA_ACHA16 F 25 24 18 2 RNAseq 
ITA_ACHA75 F 75 58 15 25 IHC 
ITA_ACHA37 F 64 61 18 4 RNAseq/RT-qPCR/wb/IHC 
ITA_ACHA34 M 58 57 35 20 /wb 
ITA_ACHA02 F 37 34 25 4 wb/IHC 
ITA_ACHA73 M 81 78 28 4 wb 
ITA_ACHA33 M 68 67 44 2 RNAseq/RT-qPCR/wb/IHC 
ITA_ACHA25 M 66 64 22 3 wb 
ITA_ACHA78 F 36 36 15 1 IHC 
ITA_ACHA66 F 41 40 23 20 wb 
BE_ACHA5051 F 16 16 37 6 IHC 
BE_ACHA5208 M 69 69 naa)  7 IHC 
BE_ACHA5691 F 82 82 na 2.5 IHC 
BE_ACHA6936 F 20 20 38 2 IHC 
BE_ACHA7521 F 63 63 35.3 0.42 IHC 
BE_ACHA5466 M 22 22 27.5 1 IHC 
BE_ACHA5768 M 44 44 33 1.5 IHC 
BE_ACHA6790 F 69 69 35.6 2 IHC 
BE_ACHA810 M 61 61 30 15 IHC 
BE_ACHA8705 M 65 65 na 10 IHC 
BE_ACHA1059 M 28 28 naa)  7 IHC 
BE_ACHA8154 F 42 42 68 0.58 IHC 
BE_ACHA302 M 50 50 51 3 IHC 
BE_ACHA479 M 50 50 34 3 IHC 
BE_ACHA7818 F 33 33 38 0.17 IHC 
BE_ACHA8199 M 24 24 103 6 IHC 
BE_ACHA8347 F 21 21 nab)  4 IHC 
































































BE_ACHA5260 F 32 32 48.3 2 IHC 
BE_ACHA5295 F 35 35 na 6 IHC 
BE_ACHA1730 M 57 57 nm 5 IHC 
BE_ACHA3017 M 49 49 42.3 2 IHC 
BE_ACHA3354 F 49 49 80.3 8 IHC 
 
Legends: na= not available; nm= not measurable; a) type I; b) type II; wb= western blotting; IHC= 
immunohistochemistry. 
 
b) controls  
 
ID patients Age Sex Pathology Surgery Histology Type of molecular analysis 
ITA_CNT_01 64 F 
Gastroesophageal 
reflux Antireflux Nissen fundoplication  - IHC 
ITA_CNT_02 45 M 
Gastroesophageal 
reflux Antireflux Nissen fundoplication - IHC 




Total gastrectomy and resection 
of the distal esophagus (10 cm 





ITA_CNT_70 55 M Megaesophagus 
Partial esophagectomy with 
gastro-esophageal reconstruction    IHC 













Total gastrectomy and resection 
of the distal esophagus (10 cm 





ITA_CNT_26 49 F 
Gastroesophageal 
reflux 
Antireflux Nissen fundoplication 
- RNAseq/wb 
ITA_CNT_23 46 F 
Gastroesophageal 
reflux 
Antireflux Nissen fundoplication  
- RNAseq/wb/IHC 






























































































Supplementary Table S2. Total read number and mean coverage of RNAseq libraries. 
 
      





ITA_ACHA16 96,763,286 63 
ITA_ACHA34 79,986,036 43 
ITA_ACHA37 85,671,948 47 
ITA_ACHA33 74,486,236 55 
ITA_CNT29 70,830,832 36 
ITA_CNT26 70,217,988 55 
ITA_CNT41 83,327,050 64 
ITA_CNT52 81,841,600 68 
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Figure 1. Differentially expressed genes in achalasia tissue. (A) Heat map showing the concordant 
differential expression observed in the tissues from achalasia patients compared to controls (for the genes 
reported in Table 1). Elaborated with MeV v4.8.1. (B) Biological processes of genes (GO-Slim Biological 
processes) differentially expressed in achalasia, as identified by PANTHER Functional Classification analysis. 
(C) Graphical output of significantly enriched protein-protein interactions determined with STRING analysis, 
showing the results of the 104 out of 111 dysregulated genes in achalasia, compared with data present in 
the STRING databases. The different colors in the figure inset identify the evidence for the different 
interactions (known; predicted; identified with other means, such as co-expression, data mining, and protein 
homology). The red square indicates c-KIT. (D) Real-time qRT-PCR data for c-KIT and INPP4B. Data from 
case and control tissue biopsies were normalized on a commercial pool of control tissue biopsies from 
esophagus. Student’s t-test was performed and P values are indicated. Bars indicate standard deviations.  
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Figure 2. Western blot analysis of differentially expressed genes. (A) Example of the protein expression 
profiles in achalasia tissues compared to control samples for c-KIT and INPP4B. Western blotting was 
repeated in at least two independent experiments. (B) Densitometric analysis of the relative intensities for c-
KIT and INPP4B. Quantitative data (mean values ± standard deviation) from different experiments obtained 
from each individual were compared using Student’s t-test for statistical analysis. For each sample, 
densitometric values were normalized on reference protein (vinculin). All experiments were carried out at 
least twice. Bars indicated standard deviations. P values are indicated in the graphs.  
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Figure 3. Immunostaining for c-KIT (A) and INPP4B (B). (A) Examples of the expression pattern for c-KIT in 
tissue biopsies from control (left) and achalasia patients (right). Arrows indicate the positive staining for c-
KIT. c-KIT staining color histograms of controls (n=6) and cases (n=18) represent the number of samples 
assessed according to the semi-quantitative score. c-KIT immunolabeling differences in cases vs. controls 
were assessed by Fisher’s exact test. (B) Examples of the expression pattern for INPP4B in tissue biopsies 
from control (left) and achalasia patients (right). INPP4B staining color histograms of controls (n=6) and 
cases (n=22) represent the number of samples assessed according to the semi-quantitative score. INPP4B 
immunolabeling differences in cases vs. controls were assessed by Fisher’s exact test. Scale bars are 100µm 
as indicated.  
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Figure 4. Phospho-Akt is down regulated in achalasia. (A) Example of the protein expression profiles in 
achalasia tissues compared to control samples of phospho-Akt (Ser473; Thr308) and total Akt. (B) 
Quantitative data (mean values ± standard deviation) from different experiments (performed in duplicate) 
obtained from each individual were compared using Student’s t-test. For each sample, densitometric values 
were normalized on reference protein (β-actin). The significantly different relative phospho-Akt (Ser473) 
levels comparing achalasia vs. control tissues, were reported in the histogram (P=0.0495, Student’s t-test). 
Bars indicate standard deviations.  
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